1-14 of 14
Li Liu
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

ctDNA Clearance as an Early Indicator of Improved Clinical Outcomes in Advanced NSCLC Treated with TKI: Findings from an Aggregate Analysis of Eight Clinical Trials

Hillary S. Andrews, Nevine Zariffa, Katherine K. Nishimura, Stephanie H. Choi, Shibing Deng, Megan Eisele, Carin R. Espenschied, Emily M. Goren, Minakshi Guha, Samuel Hong, Dilafruz Juraeva, Nicole Krämer, Li Liu, Jean-Francois Martini, Brittany A. McKelvey, Geoffrey R. Oxnard, Gary A. Pestano, Lynne Poole, Adam Rosenthal, Anna M. Szpurka, Diana Merino Vega, Christine Ward, Sameera R. Wijayawardana, Antje Hoering, Mark D. Stewart, Jeff D. Allen
Journal: Clinical Cancer Research
Clin Cancer Res OF1–OF11.
https://doi.org/10.1158/1078-0432.CCR-24-3612
Published: 22 April 2025
View articletitled, ctDNA Clearance as an Early Indicator of Improved Clinical Outcomes in Advanced NSCLC Treated with TKI: Findings from an Aggregate Analysis of Eight Clinical Trials
Open the PDF for ctDNA Clearance as an Early Indicator of Improved Clinical Outcomes in Advanced NSCLC Treated with TKI: Findings from an Aggregate Analysis of Eight Clinical Trials in another window
Includes: Supplementary data
Journal Articles

ERBB3 Overexpression is Enriched in Diverse Patient Populations with Castration-sensitive Prostate Cancer and is Associated with a Unique AR Activity Signature

Jordan E. Vellky, Brenna J. Kirkpatrick, Lisa C. Gutgesell, Mathias Morales, Ryan M. Brown, Yaqi Wu, Mark Maienschein-Cline, Lucia D. Notardonato, Michael S. Weinfeld, Ryan H. Nguyen, Eileen Brister, Maria Sverdlov, Li Liu, Ziqiao Xu, Steven Kregel, Larisa Nonn, Donald J. Vander Griend, Natalie M. Reizine
Journal: Clinical Cancer Research
Clin Cancer Res (2024) 30 (8): 1530–1543.
https://doi.org/10.1158/1078-0432.CCR-23-2161
Published: 15 April 2024
View articletitled, ERBB3 Overexpression is Enriched in Diverse Patient Populations with Castration-sensitive Prostate Cancer and is Associated with a Unique AR Activity Signature
Open the PDF for ERBB3 Overexpression is Enriched in Diverse Patient Populations with Castration-sensitive Prostate Cancer and is Associated with a Unique AR Activity Signature in another window
Includes: Supplementary data
Journal Articles

Flumatinib versus Imatinib for Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia: A Phase III, Randomized, Open-label, Multi-center FESTnd Study

Li Zhang, Li Meng, Bingcheng Liu, Yanli Zhang, Huanling Zhu, Jiuwei Cui, Aining Sun, Yu Hu, Jie Jin, Hao Jiang, Xi Zhang, Yan Li, Li Liu, Wanggang Zhang, Xiaoli Liu, Jian Gu, Jianhui Qiao, Guifang Ouyang, Xin Liu, Jianmin Luo, Ming Jiang, Xiaobao Xie, Jianyong Li, Chunting Zhao, Mei Zhang, Tonghua Yang, Jianxiang Wang
Journal: Clinical Cancer Research
Clin Cancer Res (2021) 27 (1): 70–77.
https://doi.org/10.1158/1078-0432.CCR-20-1600
Published: 04 January 2021
View articletitled, Flumatinib versus Imatinib for Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia: A Phase III, Randomized, Open-label, Multi-center FESTnd Study
Open the PDF for Flumatinib versus Imatinib for Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia: A Phase III, Randomized, Open-label, Multi-center FESTnd Study in another window
Includes: Supplementary data
Journal Articles

Identification of Deleterious NOTCH Mutation as Novel Predictor to Efficacious Immunotherapy in NSCLC

Kai Zhang, Xiaohua Hong, Zhengbo Song, Yu Xu, Chengcheng Li, Guoqiang Wang, Yuzi Zhang, Xiaochen Zhao, Zhengyi Zhao, Jing Zhao, Mengli Huang, Depei Huang, Chuang Qi, Chan Gao, Shangli Cai, Feifei Gu, Yue Hu, Chunwei Xu, Wenxian Wang, Zhenkun Lou, Yong Zhang, Li Liu
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2020) 26 (14): 3649–3661.
https://doi.org/10.1158/1078-0432.CCR-19-3976
Published: 15 July 2020
View articletitled, Identification of Deleterious NOTCH Mutation as Novel Predictor to Efficacious Immunotherapy in NSCLC
Open the PDF for Identification of Deleterious NOTCH Mutation as Novel Predictor to Efficacious Immunotherapy in NSCLC in another window
Includes: Supplementary data
Journal Articles

Combination of TMB and CNA Stratifies Prognostic and Predictive Responses to Immunotherapy Across Metastatic Cancer

Li Liu, Xue Bai, Jian Wang, Xin-Ran Tang, De-Hua Wu, Sha-Sha Du, Xiu-Ju Du, Yao-Wei Zhang, Hong-Bo Zhu, Yuan Fang, Ze-Qin Guo, Qin Zeng, Xue-Jun Guo, Zhu Liu, Zhong-Yi Dong
Journal: Clinical Cancer Research
Clin Cancer Res (2019) 25 (24): 7413–7423.
https://doi.org/10.1158/1078-0432.CCR-19-0558
Published: 13 December 2019
View articletitled, Combination of TMB and CNA Stratifies Prognostic and Predictive Responses to Immunotherapy Across Metastatic Cancer
Open the PDF for Combination of TMB and CNA Stratifies Prognostic and Predictive Responses to Immunotherapy Across Metastatic Cancer in another window
Includes: Supplementary data
Journal Articles

Lineage-Specific Alterations in Gynecologic Neoplasms with Choriocarcinomatous Differentiation: Implications for Origin and Therapeutics

Deyin Xing, Gang Zheng, Aparna Pallavajjala, J. Kenneth Schoolmeester, Yuehua Liu, Lisa Haley, Yan Hu, Li Liu, Lisa Logan, Yuan Lin, Kathryn E. Pearce, Christopher A. Sattler, Ya Chea Tsai, Russell Vang, Chien-Fu Hung, T.-C. Wu, Brigitte M. Ronnett
Journal: Clinical Cancer Research
Clin Cancer Res (2019) 25 (14): 4516–4529.
https://doi.org/10.1158/1078-0432.CCR-18-4278
Published: 15 July 2019
View articletitled, Lineage-Specific Alterations in Gynecologic Neoplasms with Choriocarcinomatous Differentiation: Implications for Origin and Therapeutics
Open the PDF for Lineage-Specific Alterations in Gynecologic Neoplasms with Choriocarcinomatous Differentiation: Implications for Origin and Therapeutics in another window
Includes: Supplementary data
Journal Articles

Development and Validation of an Ultradeep Next-Generation Sequencing Assay for Testing of Plasma Cell-Free DNA from Patients with Advanced Cancer

Filip Janku, Shile Zhang, Jill Waters, Li Liu, Helen J. Huang, Vivek Subbiah, David S. Hong, Daniel D. Karp, Siqing Fu, Xuyu Cai, Nishma M. Ramzanali, Kiran Madwani, Goran Cabrilo, Debra L. Andrews, Yue Zhao, Milind Javle, E. Scott Kopetz, Rajyalakshmi Luthra, Hyunsung J. Kim, Sante Gnerre, Ravi Vijaya Satya, Han-Yu Chuang, Kristina M. Kruglyak, Jonathan Toung, Chen Zhao, Richard Shen, John V. Heymach, Funda Meric-Bernstam, Gordon B. Mills, Jian-Bing Fan, Neeraj S. Salathia
Journal: Clinical Cancer Research
Clin Cancer Res (2017) 23 (18): 5648–5656.
https://doi.org/10.1158/1078-0432.CCR-17-0291
Published: 14 September 2017
View articletitled, Development and Validation of an Ultradeep Next-Generation Sequencing Assay for Testing of Plasma Cell-Free DNA from Patients with Advanced Cancer
Open the PDF for Development and Validation of an Ultradeep Next-Generation Sequencing Assay for Testing of Plasma Cell-Free DNA from Patients with Advanced Cancer in another window
Includes: Supplementary data
Journal Articles

The BRAF and MEK Inhibitors Dabrafenib and Trametinib: Effects on Immune Function and in Combination with Immunomodulatory Antibodies Targeting PD-1, PD-L1, and CTLA-4

Li Liu, Patrick A. Mayes, Stephen Eastman, Hong Shi, Sapna Yadavilli, Tianqian Zhang, Jingsong Yang, Laura Seestaller-Wehr, Shu-Yun Zhang, Chris Hopson, Lyuben Tsvetkov, Junping Jing, Shu Zhang, James Smothers, Axel Hoos
Journal: Clinical Cancer Research
Clin Cancer Res (2015) 21 (7): 1639–1651.
https://doi.org/10.1158/1078-0432.CCR-14-2339
Published: 31 March 2015
View articletitled, The BRAF and MEK Inhibitors Dabrafenib and Trametinib: Effects on Immune Function and in Combination with Immunomodulatory Antibodies Targeting PD-1, PD-L1, and CTLA-4
Open the PDF for The BRAF and MEK Inhibitors Dabrafenib and Trametinib: Effects on Immune Function and in Combination with Immunomodulatory Antibodies Targeting PD-1, PD-L1, and CTLA-4 in another window
Includes: Supplementary data
Journal Articles

New Gene-Immunotherapy Combining TRAIL-Lymphocytes and EpCAMxCD3 Bispecific Antibody for Tumor Targeting

Ariane Groth, Alexei V. Salnikov, Sabine Ottinger, Jury Gladkich, Li Liu, Georgios Kallifatidis, Olga Salnikova, Eduard Ryschich, Nathalia Giese, Thomas Giese, Frank Momburg, Markus W. Büchler, Gerhard Moldenhauer, Ingrid Herr
Journal: Clinical Cancer Research
Clin Cancer Res (2012) 18 (4): 1028–1038.
https://doi.org/10.1158/1078-0432.CCR-11-2767
Published: 14 February 2012
View articletitled, New Gene-Immunotherapy Combining TRAIL-Lymphocytes and EpCAMxCD3 Bispecific Antibody for Tumor Targeting
Open the PDF for New Gene-Immunotherapy Combining TRAIL-Lymphocytes and EpCAMxCD3 Bispecific Antibody for Tumor Targeting in another window
Includes: Supplementary data
Journal Articles

MicroRNA-148a Suppresses Tumor Cell Invasion and Metastasis by Downregulating ROCK1 in Gastric Cancer

Biqiang Zheng, Linhui Liang, Chunmeng Wang, Shenglin Huang, Xi Cao, Ruopeng Zha, Li Liu, Deshui Jia, Qi Tian, Jianghong Wu, Yanwei Ye, Qifeng Wang, Ziwen Long, Ye Zhou, Chunyan Du, Xianghuo He, Yingqiang Shi
Journal: Clinical Cancer Research
Clin Cancer Res (2011) 17 (24): 7574–7583.
https://doi.org/10.1158/1078-0432.CCR-11-1714
Published: 18 December 2011
View articletitled, MicroRNA-148a Suppresses Tumor Cell Invasion and Metastasis by Downregulating ROCK1 in Gastric Cancer
Open the PDF for MicroRNA-148a Suppresses Tumor Cell Invasion and Metastasis by Downregulating ROCK1 in Gastric Cancer in another window
Includes: Supplementary data
Journal Articles

Potent Antitumor Activity in Experimental Hepatocellular Carcinoma by Adenovirus-Mediated Coexpression of TRAIL and shRNA against COX-2

Qing Chen, Wenjia Lou, Junjie Shen, Leina Ma, Zhi Yang, Li Liu, Jingjing Luo, Cheng Qian
Journal: Clinical Cancer Research
Clin Cancer Res (2010) 16 (14): 3696–3705.
https://doi.org/10.1158/1078-0432.CCR-09-3097
Published: 14 July 2010
View articletitled, Potent Antitumor Activity in Experimental Hepatocellular Carcinoma by Adenovirus-Mediated Coexpression of TRAIL and shRNA against COX-2
Open the PDF for Potent Antitumor Activity in Experimental Hepatocellular Carcinoma by Adenovirus-Mediated Coexpression of TRAIL and shRNA against COX-2 in another window
Journal Articles

Treatment of Cancer with a Novel Dual-Targeted Conditionally Replicative Adenovirus Armed with mda-7/IL-24 Gene

Jingjing Luo, Qingmei Xia, Rui Zhang, Chen Lv, Wei Zhang, Yingxin Wang, Qiang Cui, Li Liu, Rong Cai, Cheng Qian
Journal: Clinical Cancer Research
Clin Cancer Res (2008) 14 (8): 2450–2457.
https://doi.org/10.1158/1078-0432.CCR-07-4596
Published: 15 April 2008
View articletitled, Treatment of Cancer with a Novel Dual-Targeted Conditionally Replicative Adenovirus Armed with mda-7/IL-24 Gene
Open the PDF for Treatment of Cancer with a Novel Dual-Targeted Conditionally Replicative Adenovirus Armed with mda-7/IL-24 Gene in another window
Journal Articles

Metabolism and Anticancer Activity of the Curcumin Analogue, Dimethoxycurcumin

Constantin Tamvakopoulos, Konstantinos Dimas, Zacharias D. Sofianos, Sophia Hatziantoniou, Zhiyong Han, Zhong-Li Liu, James H. Wyche, Panayotis Pantazis
Journal: Clinical Cancer Research
Clin Cancer Res (2007) 13 (4): 1269–1277.
https://doi.org/10.1158/1078-0432.CCR-06-1839
Published: 22 February 2007
View articletitled, Metabolism and Anticancer Activity of the Curcumin Analogue, Dimethoxycurcumin
Open the PDF for Metabolism and Anticancer Activity of the Curcumin Analogue, Dimethoxycurcumin in another window
Journal Articles

Centromere Protein H Is a Novel Prognostic Marker for Nasopharyngeal Carcinoma Progression and Overall Patient Survival

Wen-Ting Liao, Li-Bing Song, Hui-Zhong Zhang, Xing Zhang, Ling Zhang, Wan-Li Liu, Yan Feng, Bao-Hong Guo, Hai-Qiang Mai, Su-Mei Cao, Man-Zhi Li, Hai-De Qin, Yi-Xin Zeng, Mu-Sheng Zeng
Journal: Clinical Cancer Research
Clin Cancer Res (2007) 13 (2): 508–514.
https://doi.org/10.1158/1078-0432.CCR-06-1512
Published: 25 January 2007
View articletitled, Centromere Protein H Is a Novel Prognostic Marker for Nasopharyngeal Carcinoma Progression and Overall Patient Survival
Open the PDF for Centromere Protein H Is a Novel Prognostic Marker for Nasopharyngeal Carcinoma Progression and Overall Patient Survival in another window